Transgenic inhibition of interleukin-6 trans-signaling does not prevent skeletal pathologies in mucolipidosis type II mice
Abstract Severe skeletal alterations are common symptoms in patients with mucolipidosis type II (MLII), a rare lysosomal storage disorder of childhood. We have previously reported that progressive bone loss in a mouse model for MLII is caused by an increased number of bone-resorbing osteoclasts, whi...
Guardado en:
Autores principales: | Lena Marie Westermann, Anke Baranowsky, Giorgia Di Lorenzo, Tatyana Danyukova, Jamie Soul, Jean-Marc Schwartz, Gretl Hendrickx, Michael Amling, Stefan Rose-John, Christoph Garbers, Thorsten Schinke, Sandra Pohl |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aed06d1d61d54a08bc3375460b5e6bcb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling
por: Juliane Lokau, et al.
Publicado: (2021) -
Mucolipidosis tipo II: comunicación de un caso
por: Aracena A,Mariana, et al.
Publicado: (2003) -
Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro
por: Charlotte M. Flynn, et al.
Publicado: (2020) -
Mucolipidosis tipo IV en una paciente con ancestros mapuches. Caso clínico
por: Hernández Ch,Marta, et al.
Publicado: (2008) -
Interleukin 6 trans-signalling and the risk of future cardiovascular events in men and women
por: Per Eriksson, et al.
Publicado: (2021)